DEA Files a Notice of Intent to Temporarily Place 7-OH and Mitragynine Pseudoindoxyl in Schedule I Above a Concentration Threshold

7-hydroxymitragynine, sold as 7-OH, is the concentrated, opioid-like cousin of the alkaloids in kratom leaf, marketed as tablets, gummies, and shots in gas stations, smoke shops, and online marketplaces. Federal regulators have spent more than a year working to pull the most potent versions off the market, and in October 2026 they narrowed the target to products above a set potency rather than every item that contains the molecule. For the online sellers who move these products, and for the telehealth clinicians who treat opioid dependence, where that line falls is the central question. This is general information, not medical or legal advice.

What the DEA proposed

On October 14, 2026, the DEA published a document in the Federal Register, at 91 FR 65370, that it styles a proposed amendment and notice of intent. In it the agency's Administrator signals plans to issue a temporary order adding 7-OH and a chemical relative, mitragynine pseudoindoxyl, to Schedule I, the Controlled Substances Act's most restrictive tier, reserved for drugs the government treats as having high abuse potential and no accepted medical use. The controls would apply only above a set concentration, and the notice says the order will not publish before November 13, 2026.

Timing cuts two ways here. 7-OH is not controlled today, so nothing changes for it until that order issues. Mitragynine pseudoindoxyl is a different story: it is already in Schedule I under a separate temporary order from August 2026, and this action would fold it into the new threshold scheme. Once a threshold order is in force, handling an above-threshold product, including manufacturing, distribution, import, export, research, and simple possession, would carry Schedule I controls and penalties.

The threshold, in plain terms

Instead of scheduling every product that contains these molecules, the notice draws a concentration line. The proposed controls would apply when 7-OH or mitragynine pseudoindoxyl, alone or combined, is present at more than 1 mg per gram in solid preparations or more than 1 mg per milliliter in liquid preparations. A second prong applies when the ratio of mitragynine, the main alkaloid in kratom leaf, to the target substances is less than 100, a design meant to catch concentrated or enriched products while leaving traditional leaf material, where mitragynine dominates, below the line.

The DEA is blunt about the trade-off. The notice states that the threshold would let certain products stay on the market without Schedule I controls, then adds that neither HHS nor DEA has found these substances safe to use below the threshold. Staying under the line is a regulatory boundary, not a safety clearance.

Why HHS and DEA say they are acting

The case is built on how these compounds behave in the body. The notice describes 7-OH as having opioidergic activity and mitragynine pseudoindoxyl as a mu-opioid receptor agonist, the same receptor family targeted by morphine and fentanyl. That opioid activity is the core of the agency's public-safety argument, and the notice backs it with casework:

• Nine reports of death involving 7-OH in the FDA Adverse Event Reporting System (FAERS).
• DEA toxicology data identifying 7-OH in 85 cases since 2019, 55 of them fatal.
• At least 31 overdose cases involving mitragynine pseudoindoxyl, of which 25 were fatal.
• 165 poison center exposure cases from January to July 2025.
• 42 reports of 7-OH in 2025 from 12 states in the National Forensic Laboratory Information System (NFLIS).

How this fits the earlier 2025 and 2026 steps

This is the latest move in a sequence that began in July 2025, when the FDA and HHS recommended controlling concentrated 7-OH and the FDA called it an emerging opioid threat. DEA then published notices of intent on July 6, 2026 covering 7-OH and related substances, and on August 26, 2026 it issued a temporary order placing mitragynine pseudoindoxyl, along with two synthetic analogs labeled MGM-15 and MGM-16, in Schedule I with no threshold. That August order runs until August 26, 2028 unless it expires sooner or is replaced.

What changed in October is the number. HHS sent DEA a fresh recommendation dated October 8, 2026, signed by Assistant Secretary for Health Admiral Brian Christine, M.D., setting the new threshold in place of the lower one HHS had provided in July 2025. On the strength of that letter, DEA is withdrawing its July 6 notice for 7-OH and substituting the threshold approach. The net effect, if the order issues, is to move both substances onto one potency-based rule.

The legal mechanics: emergency scheduling

DEA is reaching for temporary, or emergency, scheduling under 21 U.S.C. 811(h). As the agency reads that authority, a temporary order requires a finding that the action is necessary to avoid an imminent hazard to public safety, can take effect without the usual notice-and-comment rulemaking, lasts up to two years, and can be extended by one. The notice also states that temporary scheduling orders are not subject to judicial review. DEA says it intends, separately, to pursue permanent scheduling through ordinary rulemaking under 21 U.S.C. 811(a), which would carry its own comment process.

What it means for the online market and telehealth

Online marketplaces are one of the channels the DEA names, alongside smoke shops and gas stations. If the temporary order issues, shipping an above-threshold 7-OH product across state lines becomes a Schedule I offense, which would push that trade off mainstream platforms and toward the unregulated gray market regulators have been chasing across the broader supplement and research-chemical space. Weaker products could remain, but with no safety finding behind them.

The more direct concern for clinicians is opioid risk. Because these compounds act on opioid receptors, regular use can produce dependence and withdrawal, which is the domain of regulated addiction care. Telehealth programs that treat opioid use disorder, including those that prescribe buprenorphine, operate inside a monitored system of licensed clinicians and pharmacies, unlike a 7-OH shot bought at a counter or online with no clinical oversight.

What is still uncertain, and the limits of this step

Several things are not settled. The temporary order has not published, its terms could shift before it does, and any permanent rule would move through its own process with public comment. The threshold is a policy judgment about where to draw the line, not a finding that products below it are safe. And the notice is a scheduling and enforcement action, not clinical guidance.

Anyone using 7-OH or kratom-derived products who wants to cut back or stop, especially after noticing tolerance or withdrawal, should work with a licensed clinician or a telehealth provider that treats opioid use disorder rather than stopping abruptly alone. Businesses weighing what the threshold covers should read the Federal Register notice and consult counsel. This remains general information, not medical or legal advice.